Caribou Biosciences has released long-term follow-up data from the dose escalation portion of its ANTLER Phase 1 trial of CB-010, an anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma. The data showed a 94% overall response rate (ORR) and a 69% complete response rate (CR) among the 16 patients treated. Caribou also announced an upsized underwritten public offering, raising $125 million in gross proceeds. The company received a $25 million equity investment from Pfizer to advance CB-011 development.
Caribou Biosciences Inc (NASDAQ:CRBU) reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
Concurrently, Caribou priced an upsized underwritten public offering of 19.2 million shares at $6.50 per share, with gross proceeds of $125 million.
Last week, Caribou received an equity investment of $25 million from Pfizer Inc (NYSE:PFE) to advance CB-011 development.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The data set includes all 16 patients treated in dose escalation.
In ANTLER dose escalation, three dose levels of CB-010 were evaluated (40×106, 80×106, and 120×106 CAR-T cells) in patients with multiple subtypes of aggressive r/r B-NHL.
CB-010 was generally well tolerated with adverse events consistent with autologous or allogeneic anti-CD19 CAR-T cell therapies; as previously reported, no dose-limiting toxicities (DLTs) were observed at dose levels 2 or 3 following a single DLT at dose level 1.
A 94% overall response rate (ORR; 15 of 16 patients) was observed following a single dose of CB-010. 69% of patients (11 of 16) achieved a complete response (CR).
44% of patients (7 of 16) had a CR at ≥6 months; 24 months is the longest CR maintained to date.
For the subset of patients with large B cell lymphoma (LBCL) (N=10):
- A 90% ORR (9 of 10) was observed.
- 70% (7 of 10) achieved a CR.
- 50% (5 of 10) had a CR at ≥6 months; 18 months is the longest CR maintained to date.
Caribou is enrolling second-line patients with LBCL in the ongoing dose expansion portion of the ANTLER clinical trial.
In expansion, the mid-dose and the high dose from escalation (80×106 and 120×106 CAR-T cells) are being evaluated in approximately 30 second-line patients to determine the recommended Phase 2 dose.
Caribou plans to report initial dose expansion data from the ongoing ANTLER trial in 1H 2024.
Price Action: CRBU shares are down 15.60% at $6.87 during the premarket session on the last check Friday.
Source: Markets.BusinessInsider